FRAXA Grant to Nahum Sonenberg, PhD — Effects of metformin in Fmr1 knockout mouse model of Fragile X syndrome

2015 Program Grant funded for $100,000

Nahum Sonenberg
Dr. Nahum Sonenberg, McGill University, Montreal, Canada

Mis-regulation of activity-dependent protein synthesis is one of the major cellular abnormalities found in Fragile X.  Upstream neuronal signaling regulates a large cluster of enzymes called the mTORC1 complex, which in turn regulates protein synthesis.  This complex is also controlled by cellular energy levels via the metabolic sensor AMP-activated Protein Kinase (AMPK).  AMPK is a highly conserved kinase that is activated under conditions of energy stress, when intracellular ATP levels decline and intracellular AMP increases.  AMPK normally mediates mTORC1 suppression, but AMPK appears to be decreased in Fragile X.

Metformin, an FDA-approved drug, is widely used as a first-line therapy for type 2, and is a well known activator of AMPK.  It controls gene expression at the level of mRNA translation, comparable to the mTORC1 inhibitor rapamycin. This project will explore the potential of metformin and related compounds to rescue known abnormalities in Fragile X knockout mice, and investigate its therapeutic potential.  Side effects of metformin in patients are rare, even with chronic administration, so this is a potential off-the-shelf treatment for Fragile X.

Nahum Sonenberg

Comments are closed.

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.

Share via
Copy link